Combination treatment with BRAFV600E inhibitor, vemurafenib, and BH3 mimetic, navitoclax, for BRAF mutant thyroid carcinoma.

Conclusions The results of the present study showed that vemurafenib increased the expression of anti-apoptotic proteins of the BCL-2 family. Thus, the combination of vemurafenib with navitoclax may be effective in BRAFV600E-positive PTC treatment. PMID: 30869573 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research